Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment

NCT00514475 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT00514475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00514475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
June 30, 2009
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma